Search Results - "Canva, V."

Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case by Deuffic-Burban, S., Obach, D., Canva, V., Pol, S., Roudot-Thoraval, F., Dhumeaux, D., Mathurin, P., Yazdanpanah, Y.

“…Summary We evaluated the cost‐effectiveness and the budget impact of new DAA‐based regimen use in France. A Markov model simulated chronic hepatitis C (CHC)…”
Get full text

Sanger sequencing versus INNO-LiPA® HBV PreCore assay for routine detection of precore and basal core promoter mutations in hepatitis virus B chronically infected patients by Alidjinou, E.K., Bocket, L., Pigot, V., Lambert, V., Hallaert, C., Canva, V., Hober, D.

“…We compared the Sanger sequencing and the commercial INNO-LiPA® HBV assay for the routine detection of precore (PC) and basal core promoter (BCP) mutations of…”
Get full text

A 3 year follow-up of HCV infection in opioid use disorder patients in treatment by Duburque, Clotilde, Canva, V, Auriacombe, Marc, Djomboue, P, Hernout, B, Lucidarme, D, Harbonnier, Jean

Get full text

Cost-Effectiveness and Budget Impact of Interferon-Free Direct-Acting Antiviral (DAA)-Based Regimens for Chronic Hepatitis C Treatment. The French Case by Deuffic-Burban, S, Obach, D, Canva, V, Pol, S, Roudot-Thoraval, F, Dhumeaux, D, Mathurin, P, Yazdanpanah, Y

Get full text

Safety of sofosbuvir‐based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study by Anty, R., Favre, G., Coilly, A., Rossignol, E., Houssel‐Debry, P., Duvoux, C., De Ledinghen, V., Di Martino, V., Leroy, V., Radenne, S., Kamar, N., Canva, V., D'Alteroche, L., Durand, F., Dumortier, J., Lebray, P., Besch, C., Tran, A., Canivet, C. M., Botta‐Fridlund, D., Montialoux, H., Moreno, C., Conti, F., Silvain, C., Perré, P., Habersetzer, F., Abergel, A., Debette‐Gratien, M., Dharancy, S., Esnault, V. L. M., Fougerou‐Leurent, C., Cagnot, C., Diallo, A., Veislinger, A., Danjou, H., Samuel, D., Pageaux, G.‐P., Duclos‐Vallée, J.‐C.

“…Summary Background In liver transplant recipients with hepatitis C virus recurrence, there is concern about renal safety of sofosbuvir‐based regimens. Changes…”
Get full text

Clinical and Social Psychological Profiles of Patients with Chronic Hepatitis C Treated with IFN-Free Regimens in France by Cossais, S, Schwarzinger, M, Pol, S, Fontaine, H, Larrey, D, Pageaux, G.-P, Canva, V, Mathurin, P, Yazdanpanah, Y, Deuffic- Burban, S

Get full text

P0745 : EQ-5D utility index in French patients with chronic hepatits C (CHC) infection: severe comorbidities and perceived progression of CHC infection matter more than actual liver disease stage by Schwarzinger, M, Cossais, S, Deuffic-Burban, S, Pol, S, Fontaine, H, Larrey, D, Pageaux, G.-P, Canva, V, Mathurin, P, Yazdanpanah, Y

Get full text

Meta‐analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma by Mathurin, P., Raynard, B., Dharancy, S., Kirzin, S., Fallik, D., Pruvot, F.‐R., Roumilhac, D., Canva, V., Paris, J.‐C., Chaput, J.‐C., Naveau, S.

“…Summary Aim : To evaluate adjuvant modalities after curative resection for hepatocellular carcinoma using a meta‐analysis of randomized and non‐randomized…”
Get full text

Sofosbuvir-Based-Regimen for HCV Recurrence after Combined Liver-Kidney Transplantation : Results from the ANRS CO23 Cupilt Study by Dharancy, S, Coilly, A, Fougerou-Leurent, C, Duvoux, C, Kamar, N, Leroy, V, Tran, A, Houssel-Debry, P, Canva, V, Moreno, C, Conti, F, Dumortier, J, Di Martino, V, Radenne, S, De Ledinghen, V, D’Alteroche, L, Silvain, C, Besch, C, Perré, P, Botta-Fridlund, D, Francoz, C, Habersetzer, F, Montialoux, H, Abergel, A, Debette-Gratien, M, Rohel, A, Vallée, J.C.D, Pageaux, G.-P

Get full text

Renal Dysfunction in Liver Transplant Patients Treated with Sofosbuvir Based-Regimen for HCV Recurrence: Results from a Large French Prospective Multicentric ANRS CO23 Cupilt by Anty, R, Coilly, A, Fougerou, C, De Ledinghen, V, Houssel-Debry, P, Duvoux, C, Di Martino, V, Radenne, S, Kamar, N, D’Alteroche, L, Canva, V, Lebray, P, Moreno, C, Dumortier, J, Silvain, C, Besch, C, Botta-Fridlund, D, Leroy, V, Durand, F, Tran, A, Montialoux, H, Habersetzer, F, Favre, G, Rossignol, E, Rohel, A, Renault, A, Dharancy, S, Danjou, H, Duclos-Vallee, J.-C, Pageaux, G.-P

Get full text

Should we keep using Ribavirin to Treat Hepatitis C Recurrence after Liver Transplantation? Results from the CO23 ANRS Cupilt Study by Houssel-Debry, P, Duvoux, C, Coilly, A, Fougerou-Leurent, C, Jezequel, C, De Ledinghen, V, Radenne, S, Kamar, N, Leroy, V, Di Martino, V, D’Alteroche, L, Canva, V, Conti, F, Dumortier, J, Montialoux, H, Lebray, P, Botta-Fridlund, D, Anty, R, Moreno, C, Silvain, C, Besch, C, Perre, P, Durand, F, Abergel, A, Habersetzer, F, Debette-Gratien, M, Rohel, A, Diallo, A, Rossignol, E, Veislinger, A, Danjou, H, Duclos-Vallee, J.-C, Pageaux, G.-P

“…EASL International Liver Congress, APR 13-17, 2016, Barcelona, SPAIN…”
Get full text

Anti‐viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy by Deltenre, P., Moreno, C., Tran, A., Ollivier, I., Provôt, F., Stanke, F., Lazrek, M., Castel, H., Canva, V., Louvet, A., Colin, M., Glowacki, F., Dharancy, S., Henrion, J., Hazzan, M., Noel, C., Mathurin, P.

“…Aliment Pharmacol Ther 2011; 34: 454–461 Summary Background  In end‐stage renal disease (ESRD) patients, hepatitis C virus (HCV) eradication improves patient…”
Get full text

O85 SHOULD WE AWAIT INTERFERON-FREE REGIMENS TO TREAT HCV GENOTYPE 1 TREATMENT-NAIVE PATIENTS? A COST-EFFECTIVENESS ANALYSIS (ANRS 12188) by Deuffic-Burban, S, Schwarzinger, M, Obach, D, Mallet, V, Pol, S, Pageaux, G.-P, Canva, V, Deltenre, P, Roudot-Thoraval, F, Larrey, D, Dhumeaux, D, Mathurin, P, Yazdanpanah, Y

Get full text

P1262 : An accurate score for the prediction of sustained viral response under protease inhibitor-based triple therapy in cirrhotic patients: The cupic algorithm – the ANRS CO20 CUPIC study by Boursier, J, Veillon, P, Vergniol, J, Moal, V, Dufour, C, Bronowicki, J.-P, Larrey, D, Hézode, C, Carrat, F, Zoulim, F, Fontaine, H, Poynard, T, Canva, V, Cacoub, P, Attali, P, Bourlière, M, Alric, L, Zarski, J.-P, Allam, S, Calès, P, De Lédinghen, V

Get full text

O109 : Treatment of severe HCV-recurrence after liver transplantation using sofosbuvir-based regimens: The ANRS CO23 CUPILT study by Dumortier, J, Botta-Fridlund, D, Coilly, A, Leroy, V, Fougerou-Leurent, C, Danjou, H, Radenne, S, Durand, F, Kamar, N, di Martino, V, de Ledinghen, V, Houssel-Debry, P, d’Alteroche, L, Duvoux, C, Conti, F, Canva, V, Diallo, A, Rohel, A, Duclos-Vallée, J.-C, Pageaux, G.-P

Get full text

P0137 : Safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation. Analysis from a French multicenter, open-label study (ANRS HC29 bocepretransplant) by Fontaine, H, Maynard-Muet, M, Bouix, C, Botta-Fridlund, D, D’Alteroche, L, Conti, F, Pageaux, G.-P, Leroy, V, Métivier, S, Anty, R, Durand, F, Canva, V, Lebray, P, Alric, L, Duvoux, C, Petrov-Sanchez, V, Beaulieux, F, Willems, C, Paul, C, Pradat, P, Duclos-Vallée, J.-C, Samuel, D

Get full text

P0804 : Efficacy of sofosbuvir-based treatment regimens in HIV/HCV co-infected patients after liver transplantation: The ANRS CO23 CUPILT study by Antonini, T.M, Coilly, A, Radenne, S, Veislinger, A, Botta-Fridlund, D, Durand, F, Houssel-Debry, P, Kamar, N, Canva, V, Perre, P, Bertucci, I, Dumortier, J, Leroy, V, Samuel, D, Pageaux, G.-P, Duclos-Vallee, J.-C

Get full text

G15 : The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort by Coilly, A, Fougerou, C, De Ledinghen, V, Houssel-Debry, P, Duvoux, C, Di Martino, V, Radenne, S, Kamar, N, D’Alteroche, L, Leroy, V, Canva, V, Lebray, P, Moreno, C, Dumortier, J, Silvain, C, Besch, C, Perre, P, Botta-Fridlund, D, Anty, R, Rohel, A, Renault, A, Danjou, H, Duclos-Vallee, J.-C, Pageaux, G.-P

Get full text

The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients by Boursier, J., Ducancelle, A., Vergniol, J., Veillon, P., Moal, V., Dufour, C., Bronowicki, J.-P., Larrey, D., Hézode, C., Zoulim, F., Fontaine, H., Canva, V., Poynard, T., Allam, S., De Lédinghen, V.

“…Summary Triple therapy using boceprevir or telaprevir remains the reference treatment for genotype 1 chronic hepatitis C in countries where new interferon‐free…”
Get full text

885 IMMEDIATE vs. DELAYED TREATMENT IN GENOTYPE 4-HCV INFECTED PATIENTS IN A LIMITED RESOURCES COUNTRY: A COST-EFFECTIVENESS ANALYSIS IN EGYPT (ANRS 12215) by Obach, D, Deuffic-Burban, S, Esmat, G, Anwar, W.A, Dewedar, S, Canva, V, Cousien, A, Doss, W, Mostafa, A, Pol, S, Buti, M, Siebert, U, Fontanet, A, Mohamed, M.K, Yazdanpanah, Y

Get full text